finanzen.net
22.08.2019 19:00
Bewerten
(0)

Former Novartis CEO and Eli Lilly’s Drug Development Leader are Featured Keynote Speakers at Veeva R&D Summit

Veeva Systems (NYSE:VEEV) today announced that Joe Jimenez, former CEO of Novartis, and Rob Metcalf, vice president of medicines development at Eli Lilly and Company, are featured keynote speakers at the 2019 Veeva R&D Summit. As visionaries at the forefront of breakthrough treatments in life sciences, they will discuss opportunities to speed product development throughout the industry.

Mr. Metcalf will speak on Monday, Sept. 9, about the complexities and learnings in running a major pharmaceutical research and development organization. He will discuss how to speed the delivery of breakthrough science and get the right medicines to the right people safely and efficiently.

Tuesday will feature a fireside chat with Mr. Jimenez, whose commitment to research and development led Novartis to create one of the largest pipelines of self-originated drugs in the industry. Paul Sehkri, CEO of eGenesis, a leading-edge biotech focused on xenotransplantation, will discuss with Mr. Jimenez the impact of innovations such as gene therapy on patients and life sciences R&D.

More than 55 biopharmaceutical and medical device and diagnostics professionals will share best practices using Veeva’s unified suite of applications in clinical, regulatory, and quality to speed product development. Featured sessions include:

  • AstraZeneca discussing approaches to improve collaboration and simplify trial conduct at research sites.
  • Vertex Pharmaceuticals highlighting best practices to make clinical data management teams more agile and speed database builds up to 50%.
  • Samsung BioLogics sharing its vision for modernizing manufacturing quality to meet the highest global standards and diverse customer demands.
  • GSK discussing its RIM transformation journey to improve efficiency, maintain compliance, and gain greater internal alignment across regulatory operations.

The 2019 Veeva R&D Summit takes place Sept. 8-10, 2019 in Philadelphia, PA and is expected to draw 1,700 life sciences professionals and industry experts. The annual event will include more than 75 sessions with leading life sciences companies:

  • Agios, Alkermes, Allergan, Amgen, Amicus Therapeutics, Bioforum, BioMarin Pharmaceutical, Blueprint Medicines, Bristol-Myers Squibb, Cara Therapeutics, Celularity, Daiichi Sankyo, Dicerna Pharmaceuticals, Eisai, Eli Lilly and Company, Foamix Pharmaceuticals, Gilead, Global Blood Therapeutics, Insmed, Janssen, Lotus Pharmaceutical, Melinta Therapeutics, Merck Healthcare KGaA, Myovant Sciences, Penumbra, PRA Health Sciences, REGENXBIO, Roche Diagnostics, Sarah Cannon Research Institute, TESARO a GSK Company, University of Louisville, Vericel, Xencor, and Xeris Pharma.

2019 Veeva R&D Summit platinum sponsors include Accenture, Amazon Web Services, Kinapse, NNIT, PWC, and Valiance. Gold sponsors include C3i Solutions, CGI, Daelight Solutions, Deloitte, Eagle Productivity, FME, GenPact, Ideagen PLC, LMK Clinical, LPW Training Services, MuleSoft, SDL, and Trifecta. Silver sponsors include AppBus, Base Life Sciences, OnTheMove, Pyxa Solutions, and Suvoda.

Veeva R&D Summit is a complimentary event for Veeva customers and invited guests. Learn more, register, and view the full agenda at veeva.com/R&DSummit.

Additional Information

Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
Follow @veevasystems on Twitter: twitter.com/veevasystems
Like Veeva on Facebook: facebook.com/veevasystems

About Veeva Systems

Veeva Systems Inc. is the leader in cloud-based software for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 750 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. Veeva is headquartered in the San Francisco Bay Area, with offices throughout North America, Europe, Asia, and Latin America. For more information, visit veeva.com.

Forward-looking Statements

This release contains forward-looking statements, including the market demand for and acceptance of Veeva’s products and services, the results from use of Veeva’s products and services, and general business conditions, particularly in the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva’s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva’s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva’s financial results are included under the captions, "Risk Factors” and "Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in the company’s filing on Form 10-Q for the period ended April 30, 2019. This is available on the company’s website at veeva.com under the Investors section and on the SEC’s website at sec.gov. Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.

Nachrichten zu Veeva Systems Inc (A)

  • Relevant
  • Alle
  • vom Unternehmen
  • Peer Group
  • ?

Um Ihnen die Übersicht über die große Anzahl an Nachrichten, die jeden Tag für ein Unternehmen erscheinen, etwas zu erleichtern, haben wir den Nachrichtenfeed in folgende Kategorien aufgeteilt:

Relevant: Nachrichten von ausgesuchten Quellen, die sich im Speziellen mit diesem Unternehmen befassen

Alle: Alle Nachrichten, die dieses Unternehmen betreffen. Z.B. auch Marktberichte die außerdem auch andere Unternehmen betreffen

vom Unternehmen: Nachrichten und Adhoc-Meldungen, die vom Unternehmen selbst veröffentlicht werden

Peer Group: Nachrichten von Unternehmen, die zur Peer Group gehören

Analysen zu Veeva Systems Inc (A)

  • Alle
  • Buy
  • Hold
  • Sell
  • ?
28.08.2019Veeva Systems A BuyNeedham & Company, LLC
17.04.2019Veeva Systems A BuyNeedham & Company, LLC
27.02.2019Veeva Systems A BuyNeedham & Company, LLC
05.10.2018Veeva Systems A BuyNeedham & Company, LLC
01.10.2018Veeva Systems A HoldCanaccord Adams
28.08.2019Veeva Systems A BuyNeedham & Company, LLC
17.04.2019Veeva Systems A BuyNeedham & Company, LLC
27.02.2019Veeva Systems A BuyNeedham & Company, LLC
05.10.2018Veeva Systems A BuyNeedham & Company, LLC
24.08.2018Veeva Systems A BuyNeedham & Company, LLC
01.10.2018Veeva Systems A HoldCanaccord Adams
25.11.2015Veeva System a HoldDeutsche Bank AG
04.03.2015Veeva System a HoldDeutsche Bank AG

Keine Analysen im Zeitraum eines Jahres in dieser Kategorie verfügbar.

Eventuell finden Sie Nachrichten die älter als ein Jahr sind im Archiv

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Veeva Systems Inc (A) nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"

Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"

Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen
Werbung
Werbung
Börse Stuttgart Anlegerclub

Die richtige Strategie für die Börsenkrise

Stecken Sie nicht den Sand in den Kopf, sondern kaufen Sie die richtigen Aktien. Erfahren Sie im aktuellen Anlegermagazin mehr über attraktive Qualitätsaktien und zyklische Aktien
Kostenfrei registrieren und lesen!

Veeva Systems A Peer Group News

Keine Nachrichten gefunden.

Heute im Fokus

DAX schließt wenig verändert -- Wall Street schließt etwas fester -- ZEW-Index erholt -- Siemens übernimmt PSE -- Brüssel erlaubt RWE/E.ON-Deal unter Auflagen -- WeWork, Zalando, Apple im Fokus

Beispielloser Rechtsstreit um Parlamentspause in London. Haniel will sich in jedem Fall von METRO verabschieden. AB InBev will Asiensparte für knapp 5 Milliarden Dollar an Börse bringen. Saudi Aramco stellt Kunden wohl auf Verzögerungen ein. Sony will Halbleitersparte trotz Druck von Investor behalten. CANCOM denkt anscheinend über Offerten möglicher Käufer nach.

Umfrage

Wo sehen Sie den DAX Ende 2019?

Online Brokerage über finanzen.net

finanzen.net Brokerage
Handeln Sie für nur 5 Euro Orderprovision* pro Trade aus der Informationswelt von finanzen.net!

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln
Kontakt - Impressum - Werben - Pressemehr anzeigen
Top News
Beliebte Suchen
DAX 30
Öl
Euro US-Dollar
Bitcoin
Goldpreis
Meistgesucht
Wirecard AG747206
Deutsche Bank AG514000
Daimler AG710000
NEL ASAA0B733
Ballard Power Inc.A0RENB
CommerzbankCBK100
BASFBASF11
Apple Inc.865985
Microsoft Corp.870747
EVOTEC SE566480
E.ON SEENAG99
Infineon AG623100
Amazon906866
BayerBAY001
Aurora Cannabis IncA12GS7